Pharmacist Medication Insights: Fremanezumab-vfrm (Ajovy)
Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide.
In 2018, the FDA approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.
Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks. The first in this class, erenumab-aooe (Aimovig) was approved in 2018.
Migraine headache pain is often described by patients as an intense pulsing or throbbing pain in 1 area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Migraine attacks can cause significant pain for hours to days, and can be so severe that the pain is disabling.
